Abstract
Endometriosis is one of the most common benign gynecological diseases, first described a century ago. Endometriosis is defined as ectopic endometrial tissue, usually located in the pelvis. In spite of a large number of investigations, the pathogenesis of this disorder has remained unknown. Symptomatic disease is characterized generally by pain (dysmenorrhea, dyspareunia, and pain on vaginal examination) and occasionally by a palpable mass (e.g., ovarian cysts). It is assumed that endometriosis accounts for 10%–20% of all female infertility. Presently, various therapeutic approaches can be taken, once the disease is detected by laparoscopy or laparotomy. Although the surgical removal of the implants or cysts is often attempted, medical treatment is usually administered.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
American Fertility Society (1985) Revised American Fertility Society classification of endometriosis. Fertil Steril 43:351–352.
Barbieri RL (1988) New therapy for endometriosis. N Engl J Med 318:512–514.
Barbieri RL, Ryan KJ (1981) Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 141:453.
Burgus R, Butcher M, Amoss M, Ling N, Monahan MW, Rivier J, Fellows R, Blackwell R, Vale W, Guillemin R (1972) Primary structure of the ovine hypothalamic luteinizing hormone releasing factor (LRF). Proc Natl Acad Sci USA 69:278.
Cirkel U, Schweppe KW, Ochs H, Schneider HPG (1987) Metabolic effects and general side effects of endometriosis treatment with an LHRH agonist. Geburtshilfe Frauenheilkd 47:154–157.
Dlugi AM, Rufo S, D’Amico JF, Seibel MM (1988) A comparison of the effects of buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 49:913–915.
Douglass CF, Weed JC (1957) Endometriosis treated with prolonged administration of diethylstilbestrol. Obstet Gynecol 13:744.
Greenblatt RB, Dmowski WP, Mahesh VP et al. (1971) Clinical studies with an antigonadotropin danazol. Fertil Steril 22:102.
Hardt W, Schmidt-Gollwitzer M, Schmidt-Gollwitzer K, Genz T, Nevinny-Stickel J (1986) Initial results in the treatment of endometriosis with the LH-RH analog buserelin. Geburtshilfe Frauenheilkd 46:483–489.
Healy DL (1986) LHRH analogues in endometriosis. Lancet 1016-1018.
Helm K, Kiesel L, Rabe T, Runnebaum B (1988) Desensitization of pituitary cells by gonadotropin-releasing hormone in vitro. In: Runnebaum B, Rabe T, Kiesel L (eds) Female contraception. Berlin Heidelberg New York, Springer, pp 184–191.
Henzl MR, Corson SL, Moghissi K, But-tram VC, Berquist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 318:485–490.
Jelley RY (1987) Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. Br J Clin Pract 41:64–68.
Kiesel L, Runnebaum B (1989) Intracellular aspects of gonadotropin-releasing hormone. In: Vickery B (ed) Proceedings of the International Symposium on GnRH Analogue in Reproduction and Cancer. MTP Press, pp 53-70.
Kiesel L, Runnebaum B (1990) Mechanisms involved in the hormonal treatment of endometriosis. In: Chadha DR, Buttram VC jr (eds) Current concepts in endometriosis. Alan R. Liss, New York, pp 179–196.
Kiesel L, Rabe T, Schleef J, Schweizer M, Klinga K, Runnebaum B (1986) Pulsatile secretory pattern of gonadotropins and steroids during the follicular and luteal phase of the menstrual cycle in women. In: Pulsatile GnRH 1985. Proceedings of the 3rd Ferring symposium on pulsatile GnRH. Noordwijk, September 11-13, 1985. pp 43-49 Haarlem, Ferring.
Kiesel L, Thomas K, Tempone A, Trabant H, Widdra W, Runnebaum B (1989) Efficacy and safety of buserelin treatment in women with endometriosis — a multicentre open-label study. Gynecol Endocrinol 3 [Suppl 2], pp 5–19.
Kiesel L, Braun S, Bertges K, Schaible A, Scharia S, Minne HW, Runnebaum B (1990) Bone mineral density in patients treated with intranasal buserelin for endometriosis: a randomized study for calcium supplementation. In: Brosens I, Jacobs HS, Runnebaum B (eds) LHRH analogues in gynaecology. Parthenon, Carnforth (Lanes), pp 179–188.
Kistner R (1959) The treatment of endometriosis by inducing pseudopregnan-cy with ovarian hormones. A report of 58 cases. Fertil Steril 10:539.
Lemay A, Quesnel G (1982) Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 38:376–379.
Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41:863–871.
Lemay A, Maheux R, Huot C, Blanchet J, Faure N (1988) Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol 158:233–236.
Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV (1971) Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43:1334.
Matta WH, Shaw RW (1987) A comparative study between buserelin and danazol in the treatment of endometriosis. Br J Clin Pract 41:69–72.
Meldrum DR, Chang RJ, Lu J, Vale W, Rivier J, Judd HL (1982) Medical oophorectomy using a long-acting GnRH agonist — a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 54:1081–1083.
Olive DL, Haney AF (1986) Endometrio-sis-associated infertility: a critical review of therapeutic approaches. Obstet Gynecol 41:538–555.
Sandow J (1983) Clinical applications of LHRH and its analogues. Clin Endocrinol 18:571–592.
Schriock E, Monroe SE, Henzl M, Jaffe RB (1985) Treatment of endometriosis with a potent agonist of gonadotropin-re-leasing hormone (nafarelin). Fertil Steril 44:583–588.
Schweppe KW, Wynn RM (1984) Endocrine dependency of endometriosis: an ultrastructural study. Eur J Obstet Gynecol Reprod Biol 17:193–208.
Shaw RW, Fraser HM, Boyle H (1983) Intranasal treatment with luteinizing hormone-releasing hormone agonist in women with endometriosis. Br Med J 287:1667–1669.
Tummon IS, Ali A, Pepping ME, Rad-wanska E, Binor Z, Dmowski WP (1988) Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 49:792–796.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kiesel, L., Rabe, T., Runnebaum, B. (1992). Endocrine Treatment of Endometriosis. In: Bastert, G., Wallwiener, D. (eds) Lasers in Gynecology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45683-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-45683-1_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45685-5
Online ISBN: 978-3-642-45683-1
eBook Packages: Springer Book Archive